Clinical trials: Vasculitis, Central Nervous System
Giant Cell Arteritis, Acute Phase
Study of Circulating Microparticles in Giant Cell Arteritis
To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex…
- Trial name
- MicroGiant (NCT02333708)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Cerebral Ischemia, Takayasu Arteritis
Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)
The aim of this study is to evaluate the safety and efficacy of remote ischemic conditioning ( RIC ) in the protection of cerebral ischemia in patients with Takayasu arteritis ( TAK ).
- Trial name
- TARIC-1 (NCT06178419)
- Testing
- RIC
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Xuanwu Hospital, Beijing
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis.
- Trial name
- NCT01613599
- Testing
- Rituximab
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Arteritis, Giant Cell, Blindness and Low Vision
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO
Giant cell arteritis , also named Horton's disease, is the most common vasculitis in subjects over 50 years old. The incidence increases with age : from 188 to 290 cases per million inhabitants per year, with a North-South…
- Trial name
- CECIBO (NCT03841734)
- Testing
- treatment
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Vasculitis, Systemic Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
This study seeks to understand the journey that patients eventually are diagnosed with vasculitis experience in the period prior to their formal diagnosis by a healthcare provider.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT03410290
- Testing
- Online Questionnaire
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA).
- Trial name
- NCT03244709
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Hospital of Prato
Giant Cell Arteritis
Giant Cell Arteritis - Optimization of Diagnostics
Giant cell arteritis - Optimization of diagnostics
- Trial name
- GAME (NCT05248906)
- Testing
- Giant cell arteritis
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
The purpose of this pilot study is to test whether an 8-week course of glucocorticoids, combined with rituximab, is effective in treating ANCA-associated vasculitis.
- Trial name
- SCOUT (NCT02169219)
- Testing
- Glucocorticoids, Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Temporal Arteritis
Diagnostic Study of Temporal Arteritis
Despite a large and growing body of knowledge concerning the diagnosis of temporal arteritis, this potentially crippling disease still requires pathological diagnosis in practically every case.
- Trial name
- NCT01130857
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Vasculitis, Microscopic Polyangiitis
Alemtuzumab for ANCA Associated Refractory Vasculitis
Overview: This open label, randomized, multi-centre study will enroll and treat 24 patients with refractory AAV. Aims: To determine the clinical response and severe adverse event rates associated with alemtuzumab therapy among…
- Conditions
- Vasculitis, Microscopic Polyangiitis, Granulomatosis With Polyangiitis, Wegener's
- Trial name
- ALEVIATE (NCT01405807)
- Testing
- Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Wegener's Granulomatosis, Microscopic Polyangiitis
Plasma Exchange for Renal Vasculitis
The purpose of this study is to test whether additional therapy with plasma exchange improves the chances of kidney recovery in severe kidney vasculitis.
- Trial name
- MEPEX (NCT01408836)
- Testing
- Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Giant Cell Arteritis, Optic Ischaemic Neuropathy
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains.
- Trial name
- TOCIAION (NCT04239196)
- Testing
- tocilizumab and IV steroids combination, IV steroids combination alone
- Where
- 10 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA)
Special Drug Use-results Survey for Long-term Use（Avacopan）
The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.
- Trial name
- NCT06758271
- Testing
- Avacopan
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy
Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
Giant cell arteritis (GCA) is an inflammation of the blood vessels. A dangerous complication is sudden vision loss due to insufficient blood supply to the optic nerve.
- Conditions
- Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
- Trial name
- VISION-GCA (NCT07206238)
- Testing
- Positron Emission Tomography / Magnetic Resonance Imaging
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Microscopic Polyangiitis (MPA)
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic polyangiitis without any bad prognosis marker increases the remission…
- Trial name
- RITUXGOPRO (NCT03920722)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis, Polymyalgia Rheumatica
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR).
- Trial name
- GCAIO (NCT06460142)
- Testing
- Aortic/ cardiac magnetic resonance imaging, Vascular ultrasound, Transorbital Ultrasound
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis
Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
Ultrasound evaluation of the temporal and axillary arteries is currently well recognized in the field of giant cell arteritis (GCA), a disease primarily affecting medium- and large-caliber vessels.
- Trial name
- ALERT (NCT06894602)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis (GCA)
Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)
We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses.
- Trial name
- GIDEON (NCT07720804)
- Testing
- Blood tests to measure CRP
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Granulomatosis With Polyangiitis
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis are rare diseases characterized by inflammation of blood vessels.
- Trial name
- NeutroVasc (NCT01862068)
- Testing
- Blood samples and clinical data, Blood sample
- Where
- France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
This is a multicenter, interventional, open-label, long-term extension study of Study WA28119 (NCT01791153) to evaluate the long-term safety of SC tocilizumab in participants with GCA who subsequently have flare or persisting…
- Trial name
- NCT03202368
- Testing
- Tocilizumab
- Where
- 3 sites in France
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche